Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease.

Tzouvelekis A, Karampitsakos T, Bouros E, Tzilas V, Liossis SN, Bouros D.

Clin Chest Med. 2019 Sep;40(3):679-691. doi: 10.1016/j.ccm.2019.06.002. Review.

PMID:
31376900
2.

Diagnostic value of BAL lymphocytosis in patients with indeterminate for UIP imaging pattern.

Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntasiou M, Katsaras M, Costabel U, Wells A, Bouros D.

Eur Respir J. 2019 Jul 18. pii: 1901144. doi: 10.1183/13993003.01144-2019. [Epub ahead of print] No abstract available.

PMID:
31320457
3.

Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D.

Chest. 2019 Aug;156(2):383-391. doi: 10.1016/j.chest.2019.04.114. Epub 2019 May 22. Review.

PMID:
31125557
4.

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.

Tzilas V, Bouros E, Barbayianni I, Karampitsakos T, Kourtidou S, Ntassiou M, Ninou I, Aidinis V, Bouros D, Tzouvelekis A.

Pulm Pharmacol Ther. 2019 Apr;55:17-24. doi: 10.1016/j.pupt.2019.01.003. Epub 2019 Jan 16.

PMID:
30659895
5.

Respiratory Function in Wind Instrument Players.

Bouros E, Protogerou V, Castana O, Vasilopoulos G.

Mater Sociomed. 2018 Oct;30(3):204-208. doi: 10.5455/msm.2018.30.204-208.

6.

Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle.

Tzilas V, Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2018;96(3):207-209. doi: 10.1159/000489936. Epub 2018 Jun 19. No abstract available.

PMID:
29920503
7.

The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.

Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, Megadoukas P, Harokopos V, Valavanis C, Chun J, Kosma A, Stathopoulos GT, Bouros E, Bouros D, Syrigos K, Aidinis V.

Cancer Res. 2018 Jul 1;78(13):3634-3644. doi: 10.1158/0008-5472.CAN-17-3797. Epub 2018 May 3.

8.

Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, Bouros D, Froudarakis ME.

Clin Respir J. 2018 Jun;12(6):2084-2089. doi: 10.1111/crj.12777. Epub 2018 Mar 12.

PMID:
29412521
9.

Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2018 Jan 24;4:257. doi: 10.3389/fmed.2017.00257. eCollection 2017.

10.

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, Ntolios P, Tzilas V, Bouros E, Steiropoulos P, Chrysikos S, Dimakou K, Koulouris N, Bouros D.

Pulm Pharmacol Ther. 2018 Apr;49:61-66. doi: 10.1016/j.pupt.2018.01.006. Epub 2018 Jan 31.

PMID:
29366978
11.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2017 Nov 29;4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017. Erratum in: Front Med (Lausanne). 2018 Jan 24;4:257.

12.

Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World".

Tzouvelekis A, Bouros E, Tzilas V, Bouros D.

Respiration. 2017;94(5):405-407. doi: 10.1159/000480299. Epub 2017 Sep 5. No abstract available.

13.

Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts.

Bouros E, Filidou E, Arvanitidis K, Mikroulis D, Steiropoulos P, Bamias G, Bouros D, Kolios G.

Pulm Pharmacol Ther. 2017 Oct;46:78-87. doi: 10.1016/j.pupt.2017.08.012. Epub 2017 Sep 1.

PMID:
28865842
14.

Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis: Thinking Outside the Box in Disease Management and Prognostication.

Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2017;94(4):334-335. doi: 10.1159/000480093. Epub 2017 Aug 26. No abstract available.

15.

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.

Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, Steiropoulos P, Koulouris N, Stratakos G, Froudarakis M, Bouros D.

Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.

PMID:
28843616
16.

Guidelines for Idiopathic Pulmonary Fibrosis: Everything Flows.

Tzilas V, Bouros E, Tzouvelekis A, Bouros D.

Respiration. 2017;93(6):401-403. doi: 10.1159/000473884. Epub 2017 Apr 27. No abstract available.

17.

Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'.

Tomos IP, Tzouvelekis A, Aidinis V, Manali ED, Bouros E, Bouros D, Papiris SA.

Expert Rev Respir Med. 2017 Apr;11(4):299-309. doi: 10.1080/17476348.2017.1300533. Epub 2017 Mar 8. Review.

PMID:
28274188
18.

Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations.

Kishore A, Žižková V, Kocourková L, Petrkova J, Bouros E, Nunes H, Loštáková V, Müller-Quernheim J, Zissel G, Kolek V, Bouros D, Valeyre D, Petrek M.

Front Immunol. 2016 Jul 11;7:274. doi: 10.3389/fimmu.2016.00274. eCollection 2016.

19.

A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D.

J Transl Med. 2013 Jul 15;11:171. doi: 10.1186/1479-5876-11-171.

20.

Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis.

Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D.

Pulm Med. 2012;2012:143637. doi: 10.1155/2012/143637. Epub 2012 May 10.

21.

Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, Kolios G, Bouros D.

Pulm Med. 2011;2011:849035. doi: 10.1155/2011/849035. Epub 2011 Nov 1.

22.

Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D.

J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182.

Supplemental Content

Loading ...
Support Center